Contineum Therapeutics, Inc. Logo

Contineum Therapeutics, Inc.

Develops oral small molecule therapies for neurological, inflammatory, and fibrotic diseases.

CTNM | US

Overview

Corporate Details

ISIN(s):
US21217B1008
LEI:
Country:
United States of America
Address:
3565 GENERAL ATOMICS COURT, SUITE 200, 92121 SAN DIEGO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company that discovers and develops novel, oral small molecule therapies. The company focuses on pioneering treatments for conditions at the intersection of neuroscience, inflammation, and immunology (NI&I). Its pipeline is based on clinically validated biological targets and includes a potential best-in-class LPA1R antagonist for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PrMS), and a potential first-in-class M1R antagonist for major depressive disorder (MDD) in collaboration with a Johnson & Johnson company. Formerly Pipeline Therapeutics, Contineum aims to develop impactful treatments for serious neurological, inflammatory, and fibrotic diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Contineum Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Contineum Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Contineum Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.